Oral iron chelators: Prospects for future development

Oral iron chelators: new opportunities and new dilemmas.

Thalassemia: cardiac iron and chelators.

1. Díez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148:293-300. 2. Leth H, Andersen KK, Frystyk J, Tarnow L, Rossing P, Paeving HH, et al. Elevated levels of high-molecularweight adiponectin in type 1 diabetes. J Clin Endocrinol Metab. 2008;93:3186-91. 3. Oh DK, Ciaraldi T, Henry RR. Adiponectin in health and disease. Dia...

Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.

For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation. Despite dramatic gains in life expectancy in the deferoxamine era for patients with transfusion-dependent anemias, the leading cause of death for young adults with thalassemia major and related disorders has been cardiac disease from myocardial iron deposition. Stra...

In vivo testing of oral iron chelators intended for clinical use.

The effectiveness of 1,2-dimethyl-3-hydroxypyrid-4-one (Ll) in increasing iron excretion in iron-loaded patients improved the propsects for replacing desferrioxamine (DF) with an oral chelating drug.’,’ L1 belongs to a new group of iron chelators, the a-ketohydroxypyridines (KHP); which are cheap to p ~ e p a r e ~ . ~ and orally active. Recently, a detailed article by Porter et al.’ on in vivo...

Conservatism Research : Historical Development and Future Prospects

=1336517. Easton, P. D., 1999. Security returns and the value relevance of accounting data. Accounting Horizons 13 (4),